Literature DB >> 18953806

Impact of surgical treatment on outcomes for papillary thyroid cancer.

Karl Y Bilimoria1, Kyle Zanocco, Cord Sturgeon.   

Abstract

Based on data from SEER and the NCDB, the contemporary dominant practice pattern in the United States for patients with PTC > or =1.0 cm is a total or near-total thyroidectomy. Only approximately 10% of patients with such tumors currently undergo hemithyroidectomy. Patients from older age groups, minority ethnic groups, and the lower socioeconomic strata dominate the set of patients who undergo hemithyroidectomy. Moreover, patients at low-volume and community hospitals are less likely to undergo total thyroidectomy. These differences in practice patterns likely reflect disparities in access to health care, medication, and comprehensive cancer centers. Critics of total or near-total thyroidectomy for PTC have historically commented that "an operation not worth doing, is not worth doing well." Such comments are no longer appropriate now that compelling data exist that show an improvement in survival and recurrence after more extensive thyroid resection. If all patients with PTC > or =1.0 cm were to instead undergo total thyroidectomy, the estimated improvement in long-term survival would be approximately 2%. The differences in outcomes seem relatively small when expressed as a percentage; however, the number of patients affected would be relatively large. The incidence of these small (<2 cm, PTCs has been increasing, and now greater than 50% of the PTC in the NCDB fall into the less than 2-cm size category. There are several valid reasons why surgeons may not perform a total thyroidectomy. Hemithyroidectomy is the appropriate operation for patients with unilateral cancers who will not or cannot comply with lifelong thyroid hormone replacement. Surgical decision making may also be influenced by concerns about the risk of devastating complications such as bilateral recurrent laryngeal nerve injury or permanent hypocalcemia, neither of which are a concern with a lobectomy. Population-based volume-outcome studies have suggested that the risk of nerve injury and hypocalcemia is significantly greater at low-volume centers. Importantly, the majority of patients in the United States undergo thyroid surgery at low-volume centers. Unless the surgeon's complication rate for thyroidectomy is substantially lower than the 2% improvement in survival rate offered by the more extensive operation, total thyroidectomy should not be offered. Alternatively, patients could be referred, if possible, to high-volume surgeons to minimize the risk of complications while offering the operation that affords the best long-term outcomes. Total or near-total thyroidectomy for PTCs greater than 1 cm in size yields the best outcome in terms of risk of recurrence and death. The surgical treatment of PTC needs to be individualized, however. based on the patient, the tumor, and the experience of the surgeon to offer the best outcome.

Entities:  

Mesh:

Year:  2008        PMID: 18953806     DOI: 10.1016/j.yasu.2008.03.001

Source DB:  PubMed          Journal:  Adv Surg        ISSN: 0065-3411


  10 in total

1.  Lobectomy and prophylactic central neck dissection for papillary thyroid microcarcinoma: do involved lymph nodes mandate completion thyroidectomy?

Authors:  Cho Rok Lee; Haiyoung Son; Sohee Lee; Sang-Wook Kang; Jong Ju Jeong; Kee-Hyun Nam; Woong Youn Chung; Cheong Soo Park
Journal:  World J Surg       Date:  2014-04       Impact factor: 3.352

2.  Current management of papillary thyroid microcarcinoma in Canada.

Authors:  Mazin Merdad; Antoine Eskander; John De Almeida; Jeremy Freeman; Lorne Rotstein; Shereen Ezzat; Anna M Sawka; David P Goldstein
Journal:  J Otolaryngol Head Neck Surg       Date:  2014-08-14

3.  Surgical approach and radioactive iodine therapy for small well-differentiated thyroid cancer.

Authors:  D P Momesso; F Vaisman; L S C Caminha; C H C N Pessoa; R Corbo; M Vaisman
Journal:  J Endocrinol Invest       Date:  2014-01-08       Impact factor: 4.256

Review 4.  Management of low-risk papillary thyroid carcinoma: unique conventional policy in Japan and our efforts to improve the level of evidence.

Authors:  Iwao Sugitani; Yoshihide Fujimoto
Journal:  Surg Today       Date:  2010-02-24       Impact factor: 2.549

5.  Difficulties in deciding whether to ablate patients with putatively "low-intermediate-risk" differentiated thyroid carcinoma: do guidelines mainly apply in the centres that produce them? Results of a retrospective, two-centre quality assurance study.

Authors:  Savvas Frangos; Ioannis P Iakovou; Robert J Marlowe; Nicolaos Eftychiou; Loukia Patsali; Anna Vanezi; Androulla Savva; Vassilis Mpalaris; Evanthia I Giannoula
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-01       Impact factor: 9.236

6.  Comparison of day 3 and day 5 thyroglobulin results after thyrogen injection in differentiated thyroid cancer patients.

Authors:  Sait Sager; Esra Hatipoglu; Burcak Gunes; Sertac Asa; Lebriz Uslu; Kerim Sönmezoğlu
Journal:  Ther Adv Endocrinol Metab       Date:  2018-04-17       Impact factor: 3.565

Review 7.  Volume, outcomes, and quality standards in thyroid surgery: an evidence-based analysis-European Society of Endocrine Surgeons (ESES) positional statement.

Authors:  Kerstin Lorenz; Marco Raffaeli; Marcin Barczyński; Leyre Lorente-Poch; Joan Sancho
Journal:  Langenbecks Arch Surg       Date:  2020-06-10       Impact factor: 3.445

8.  Magnesemia: an independent risk factor of hypocalcemia after thyroidectomy.

Authors:  Wenlong Wang; Chaoyang Meng; Qianhui Ouyang; Jing Xie; Xinying Li
Journal:  Cancer Manag Res       Date:  2019-09-03       Impact factor: 3.989

9.  Late recurrence of a papillary thyroid carcinoma 37 years after hemithyroidectomy: Solitary, left cervical lymph node metastasis evident on fluorodeoxyglucose positron-emission tomography/computed tomography images revealing nodular uptake.

Authors:  Hiroaki Kunogi; Yutaka Naoi; Toshiharu Matsumoto; Yutaka Ozaki
Journal:  World J Nucl Med       Date:  2020-01-29

10.  Impact of healthcare services on thyroid cancer incidence among World Trade Center-exposed rescue and recovery workers.

Authors:  David G Goldfarb; Hilary L Colbeth; Molly Skerker; Mayris P Webber; David J Prezant; Christopher R Dasaro; Andrew C Todd; Dana Kristjansson; Jiehui Li; Robert M Brackbill; Mark R Farfel; James E Cone; Janette Yung; Amy R Kahn; Baozhen Qiao; Maria J Schymura; Paolo Boffetta; Charles B Hall; Rachel Zeig-Owens
Journal:  Am J Ind Med       Date:  2021-07-18       Impact factor: 3.079

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.